Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoh Takekuma

Showing results (31-40 of 186) with videos related to

Pageof 19
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 29, 2025
Baseline hypoalbuminemia enhances regorafenib-induced problematic fatigue development in real-world metastatic colorectal cancer treatmentYoshitaka Saito, Yoh Takekuma, Yoshito Komatsu, et al.
Biopharmaceutics & Drug Disposition|December 28, 2016
Inhibitory effect of ezetimibe can be prevented by an administration interval of 4 h between α-tocopherol and ezetimibeShunsuke Nashimoto, Yuki Sato, Yoh Takekuma, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 23, 2022
Evaluation of risk factors associated with carboplatin and nab-paclitaxel treatment suspension in patients with non-small cell lung cancerYoshitaka Saito, Yoh Takekuma, Naofumi Shinagawa, et al.
Scientific Reports|November 6, 2024
Impact of renal impairment on early development of severe neutropenia with trifluridine/tipiracil treatment for metastatic colorectal cancerYoshitaka Saito, Yoh Takekuma, Yoshito Komatsu, et al.
International Journal of Clinical Oncology|June 15, 2023
Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancerYoshitaka Saito, Yoh Takekuma, Yoshito Komatsu, et al.
Journal of Intensive Care|March 24, 2023
Onset timing and duration of augmented renal clearance in a mixed intensive care unitRyusei Mikami, Mineji Hayakawa, Shungo Imai, et al.
In Vivo (Athens, Greece)|August 26, 2024
Risk Factor Analysis for Anti-epidermal Growth Factor Receptor Monoclonal Antibody-induced Problematic Skin Toxicities in Patients With Liver Metastatic Colorectal CancerYoshitaka Saito, Kazuki Uchiyama, Yoh Takekuma, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 6, 2023
Evaluation of the additional prophylactic effect of topical steroid ointment to systemic minocycline against anti-epidermal growth factor antibody-induced skin toxicities in metastatic colorectal cancer treatmentYoshitaka Saito, Kazuki Uchiyama, Yoh Takekuma, et al.
Case Reports in Oncology|June 29, 2023
Temporary Severe Neutropenia during Administration of Atezolizumab: A Novel Case ReportRyota Kanno, Yoshitaka Saito, Yoh Takekuma, et al.
International Journal of Clinical Oncology|July 8, 2023
Acid suppressants reduce the therapeutic effect of immune checkpoint inhibitors and increase the risk of acute kidney injury: a meta-analysisKeisuke Okamoto, Yoshitaka Saito, Atsushi Yamaguchi, et al.
Pageof 19

Showing results (31-40 of 186) with videos related to

Sort By:
Pageof 19
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 29, 2025
Baseline hypoalbuminemia enhances regorafenib-induced problematic fatigue development in real-world metastatic colorectal cancer treatmentYoshitaka Saito, Yoh Takekuma, Yoshito Komatsu, et al.
Biopharmaceutics & Drug Disposition|December 28, 2016
Inhibitory effect of ezetimibe can be prevented by an administration interval of 4 h between α-tocopherol and ezetimibeShunsuke Nashimoto, Yuki Sato, Yoh Takekuma, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 23, 2022
Evaluation of risk factors associated with carboplatin and nab-paclitaxel treatment suspension in patients with non-small cell lung cancerYoshitaka Saito, Yoh Takekuma, Naofumi Shinagawa, et al.
Scientific Reports|November 6, 2024
Impact of renal impairment on early development of severe neutropenia with trifluridine/tipiracil treatment for metastatic colorectal cancerYoshitaka Saito, Yoh Takekuma, Yoshito Komatsu, et al.
International Journal of Clinical Oncology|June 15, 2023
Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancerYoshitaka Saito, Yoh Takekuma, Yoshito Komatsu, et al.
Journal of Intensive Care|March 24, 2023
Onset timing and duration of augmented renal clearance in a mixed intensive care unitRyusei Mikami, Mineji Hayakawa, Shungo Imai, et al.
In Vivo (Athens, Greece)|August 26, 2024
Risk Factor Analysis for Anti-epidermal Growth Factor Receptor Monoclonal Antibody-induced Problematic Skin Toxicities in Patients With Liver Metastatic Colorectal CancerYoshitaka Saito, Kazuki Uchiyama, Yoh Takekuma, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 6, 2023
Evaluation of the additional prophylactic effect of topical steroid ointment to systemic minocycline against anti-epidermal growth factor antibody-induced skin toxicities in metastatic colorectal cancer treatmentYoshitaka Saito, Kazuki Uchiyama, Yoh Takekuma, et al.
Case Reports in Oncology|June 29, 2023
Temporary Severe Neutropenia during Administration of Atezolizumab: A Novel Case ReportRyota Kanno, Yoshitaka Saito, Yoh Takekuma, et al.
International Journal of Clinical Oncology|July 8, 2023
Acid suppressants reduce the therapeutic effect of immune checkpoint inhibitors and increase the risk of acute kidney injury: a meta-analysisKeisuke Okamoto, Yoshitaka Saito, Atsushi Yamaguchi, et al.
Pageof 19